Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey

被引:35
|
作者
Moon, Joon Ho [1 ]
Koo, Bo Kyung [1 ,2 ]
Kim, Won [1 ,3 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Metropolitan Govt, Boramae Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[3] Seoul Metropolitan Govt, Boramae Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Non-alcoholic fatty liver disease; Sarcopenia; Mortality; Nationwide survey; FIBROSIS STAGE; ASSOCIATION; DIAGNOSIS; RISK; MANAGEMENT; AGE; INFLAMMATION; FEATURES; OUTCOMES;
D O I
10.1002/jcsm.12719
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background Sarcopenia is an independent risk factor not only for advanced-stage non-alcoholic fatty liver disease (NAFLD) but also for mortality. We investigated the association of sarcopenia and/or NAFLD with mortality among the Korean general population. Methods Individuals aged 35-75 years without any history of cancer, ischaemic heart disease, ischaemic stroke, or secondary causes of chronic liver disease were selected from the Korean National Health and Nutrition Examination Surveys from 2008 to 2015. Their mortality data until December 2018 were retrieved from the National Death Registry. NAFLD and sarcopenia were defined by hepatic steatosis index and appendicular skeletal muscle mass divided by body mass index (BMI), respectively. Results A total of 28 060 subjects were analysed [mean age, 50.6 (standard error, 0.1) years, 48.2 (0.3) % men]; the median follow-up duration was of 6.8 (interquartile range, 4.8, 8.4) years. NAFLD predicted mortality after adjustment for age, sex, BMI, hypertension, dyslipidaemia, and smoking (HR 1.32, 95% CI 1.03-1.70), but this prediction lost its statistical significance after additional adjustment for diabetes mellitus. In contrast, NAFLD with advanced fibrosis independently increased the risk of mortality after adjustment for all covariates (HR 1.68, 95% CI 1.02-2.79). Stratified analysis revealed that NAFLD and sarcopenia additively increased the risk of mortality as an ordinal scale (HR 1.46, 95% CI 1.18-1.81, P for trend = 0.001). The coexistence of NAFLD and sarcopenia increased the risk of mortality by almost twice as much, even after adjustment for advanced fibrosis (HR 2.18, 95% CI 1.38-3.44). Conclusions Concurrent NAFLD and sarcopenia conferred a two-fold higher risk of mortality. The observation that NAFLD and sarcopenia additively increase mortality suggests that risk stratification would be helpful in predicting mortality among those with metabolic derangement.
引用
收藏
页码:964 / 972
页数:9
相关论文
共 50 条
  • [21] Platelets in Non-alcoholic Fatty Liver Disease
    Dalbeni, Andrea
    Castelli, Marco
    Zoncape, Mirko
    Minuz, Pietro
    Sacerdoti, David
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease
    Zambon Azevedo, Vittoria
    Silaghi, Cristina Alina
    Maurel, Thomas
    Silaghi, Horatiu
    Ratziu, Vlad
    Pais, Raluca
    FRONTIERS IN NUTRITION, 2022, 8
  • [23] Influence of non-alcoholic fatty liver disease on non-variceal upper gastrointestinal bleeding: A nationwide analysis
    Soni, Aakriti
    Yekula, Anuroop
    Singh, Yuvaraj
    Sood, Nitish
    Dahiya, Dushyant Singh
    Bansal, Kannu
    Abraham, G. M.
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (01) : 79 - 88
  • [24] Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities
    Onnerhag, Kristina
    Dreja, Karl
    Nilsson, Peter M.
    Lindgren, Stefan
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (05) : 542 - 550
  • [25] The Roles of Non-Pharmacologic and Emerging Pharmacologic Management of Non-alcoholic Fatty Liver Disease and Sarcopenia: A Narrative Review
    Rivera, Frederick Berro
    Adizas, Arcel
    Cubarrubias, Deanna
    Bantayan, Nathan Ross
    Choi, Sarang
    Carado, Genquen Philip
    Yu, Marc Gregory
    Lerma, Edgar
    Vijayaraghavan, Krishnaswami
    JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES, 2024, 39 (01): : 84 - 94
  • [26] Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
    Valenzuela-Vallejo, Laura
    Sanoudou, Despina
    Mantzoros, Christos S.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (05):
  • [27] Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)
    Bica, Cristina
    Sandu, Camelia
    Suceveanu, Andra Iulia
    Sarbu, Eliza
    Stoica, Roxana Adriana
    Gherghiceanu, Florentina
    Bohiltea, Roxana Elena
    Stefan, Simona Diana
    Stoian, Anca Pantea
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (03) : 2387 - 2391
  • [28] Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study
    Han, Byoungduck
    Lee, Gyu Bae
    Yim, Sun Young
    Cho, Kyung-Hwan
    Shin, Koh Eun
    Kim, Jung-Hwan
    Park, Yong-Gyu
    Han, Kyung-Do
    Kim, Yang-Hyun
    DIAGNOSTICS, 2022, 12 (03)
  • [29] Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study
    Lee, Young In
    Lim, Young-Suk
    Park, Hye Soon
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (01) : 91 - 95
  • [30] Is mean platelet volume a simple marker of non-alcoholic fatty liver disease?
    Karaogullarindan, Umit
    Uskudar, Oguz
    Odabas, Emre
    Saday, Melike
    Akkus, Gamze
    Delik, Anil
    Gumurdulu, Yuksel
    Kuran, Sedef
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2023, 42 (02) : 219 - 225